Jeffery Kutok
Chief Scientific Officer Ensem Therapeutics
Seminars
Thursday 10th September 2026
ETX-929, A Potential Best-In-Class, Oral, Highly Potent & Selective Dual ON / OFF State Pan-KRAS Small Molecule Inhibitor for the Treatment of KRAS Mutant & Wild-type Amplified Cancers
2:00 pm
- Kinetic Ensemble platform enabled the development of a mutation agnostic panKRAS inhibitor that engages all KRAS mutant and WT alleles while targeting both active (ON) and inactive (OFF) KRAS states
- Demonstrates how high level drug design choices enable superior selectivity and performance versus competitors restricted to switch II, single state binding
- Optimized drug like properties and exposure profiles to overcome historical bioavailability challenges that limited earlier allele specific KRAS therapies – at IND/Ph1 stage
